To assess Trop‐2 expression levels, Western blotting, and flow cytometry were performed on a panel of prostate cancer (PCa) cell lines, including 22Rv1, C4‐2B, PC‐3, DU‐145, and LNCaP. The gene discussed is TACSTD2; the disease is posterior cortical atrophy.